SQOR regulates H2S detoxification and lipid metabolism to maintain glioblastoma metabolic fitness

Cancer is often described as a disease of uncontrolled growth, but for the most aggressive form of brain tumor, known as glioblastoma, the real challenge is survival in a hostile environment. These tumors must constantly adapt to shifting supplies of oxygen and nutrients within the brain, a process that requires a highly flexible internal engine. To keep running, cancer cells rewire their metabolism, the chemical processes that turn food into energy. One critical part of this process involves sulfur, an element found in many foods and essential for building proteins. Cells naturally produce a gas called hydrogen sulfide as a byproduct of handling sulfur. While this gas is toxic in high amounts, cells also use it for signaling. The central puzzle for scientists has been how these tumors manage to produce this gas without poisoning themselves, and whether this delicate balance could be broken to stop the cancer.

A team of researchers at the Cleveland Clinic and other institutions has now identified a specific protein that acts as a safety valve for this process. They found that glioblastoma cells rely heavily on an enzyme called sulfide quinone oxidoreductase, or SQOR, to manage their sulfur waste. This enzyme does more than just clean up; it captures the energy from the toxic gas and feeds it directly into the cell's power plant, the mitochondria. By doing so, the tumor turns a potential poison into a source of fuel, allowing it to keep growing even when conditions are tough. The researchers discovered that when they blocked this enzyme, the cancer cells could no longer handle their own waste. The toxic gas built up, the power plant stalled, and the cells were forced into a desperate, inefficient mode of survival that ultimately led to their collapse.

The study began by looking at the metabolic habits of glioblastoma in mice. The researchers observed that these tumors were actively processing sulfur and producing hydrogen sulfide. To test the importance of this process, they used mice that were genetically engineered to lack an enzyme that creates the gas. In these mice, the animals lived longer than those with the enzyme, suggesting that the gas itself was helping the cancer thrive. However, the researchers also noticed that the tumors responded by producing more of the cleanup enzyme, SQOR. This hinted that the cancer was not just making the gas, but was also actively working to neutralize it to keep its internal machinery running. When they looked at human tumor samples, they confirmed that SQOR levels were significantly higher in cancerous tissue than in healthy brain tissue, and the levels rose with the tumor grade.

To understand exactly what happened when this cleanup system was removed, the scientists turned to human glioblastoma cells grown in the lab. They used two different methods to stop the cells from making SQOR: one involved genetically silencing the gene that produces the enzyme, and the other used a chemical drug designed to block its activity. In both cases, the results were dramatic. Without SQOR, the cells could not get rid of the hydrogen sulfide they produced. The gas accumulated inside the cell, acting like a clog in the engine. The mitochondria, which normally burn fuel to create energy, began to fail. The cells could no longer perform oxidative phosphorylation, the efficient process of generating energy using oxygen. Instead, they were forced to switch to a much less efficient method called glycolysis, which relies on sugar but produces far less energy and creates acidic waste.

This metabolic crisis had a ripple effect throughout the cell. Because the mitochondria were struggling, the cell began to accumulate the raw materials it usually burns for fuel. Specifically, the researchers found a buildup of citrate, a key intermediate in the energy cycle. Instead of being burned for energy, this citrate was diverted into making fats. The cells began to fill up with lipid droplets, essentially storing fat they could not use. This was a critical failure of flexibility; the tumor cells had lost the ability to switch between different fuel sources. They were stuck making fat but could not burn it, and they could not burn sugar efficiently either. This metabolic rigidity proved fatal. The cells lost their ability to maintain their stem-like properties, which are crucial for the tumor's ability to regenerate and resist treatment. They stopped dividing and began to die.

The researchers also tested whether this vulnerability could be exploited to treat the disease. They treated mice with glioblastoma tumors with the chemical inhibitor that blocks SQOR. The drug successfully stopped the enzyme's activity, causing hydrogen sulfide to build up in the plasma of the treated mice. The result was a significant extension in the survival of the mice. The tumors stopped growing, and the animals lived much longer than those given a placebo. The effect was even more pronounced when the researchers combined the drug with a strategy to increase the production of hydrogen sulfide within the tumor. By forcing the cells to produce more of the gas while simultaneously blocking their ability to clean it up, they created a lethal trap that the cancer cells could not escape.

These findings suggest that glioblastoma cells have a hidden dependency on this specific cleanup pathway. They are not just surviving despite the toxic gas they produce; they have evolved to use it as a resource, provided they can manage the detoxification process. When that management system is disabled, the cell's entire energy infrastructure collapses. The study rules out the idea that the gas is purely a tumor suppressor that needs to be boosted; instead, it shows that the tumor has co-opted the gas for its own benefit, provided it has the right tools to handle it. The research also clarifies that the problem is not just the presence of the gas, but the inability to process it. The accumulation of toxic gas leads to a chain reaction: mitochondrial failure, a shift to inefficient energy production, and a dangerous buildup of unusable fats.

The work highlights a new potential target for therapy. By focusing on the enzyme SQOR, doctors might be able to disable the tumor's ability to adapt to stress. The study suggests that tumors with high levels of this enzyme might be particularly vulnerable to drugs that block it. Furthermore, the research indicates that combining such a drug with treatments that increase the production of hydrogen sulfide could make the therapy even more effective. This approach would not just starve the cancer of energy; it would force the cancer to poison itself. The findings offer a clear path forward for understanding how these aggressive tumors maintain their energy supply and provide a concrete strategy for disrupting that supply. The research does not claim to have a cure, but it has identified a critical weak point in the tumor's armor, one that could be targeted to stop the disease in its tracks.